Literature DB >> 18311148

Protein kinase CK2 links extracellular growth factor signaling with the control of p27(Kip1) stability in the heart.

Ludger Hauck1, Christoph Harms, Junfeng An, Jens Rohne, Karen Gertz, Rainer Dietz, Matthias Endres, Rüdiger von Harsdorf.   

Abstract

p27(Kip1) (p27) blocks cell proliferation through the inhibition of cyclin-dependent kinase-2 (Cdk2). Despite its robust expression in the heart, little is known about both the function and regulation of p27 in this and other nonproliferative tissues, in which the expression of its main target, cyclin E-Cdk2, is known to be very low. Here we show that angiotensin II, a major cardiac growth factor, induces the proteasomal degradation of p27 through protein kinase CK2-alpha'-dependent phosphorylation. Conversely, unphosphorylated p27 potently inhibits CK2-alpha'. Thus, the p27-CK2-alpha' interaction is regulated by hypertrophic signaling events and represents a regulatory feedback loop in differentiated cardiomyocytes analogous to, but distinct from, the feedback loop arising from the interaction of p27 with Cdk2 that controls cell proliferation. Our data show that extracellular growth factor signaling regulates p27 stability in postmitotic cells, and that inactivation of p27 by CK2-alpha' is crucial for agonist- and stress-induced cardiac hypertrophic growth.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18311148     DOI: 10.1038/nm1729

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  43 in total

1.  MicroRNA-221 inhibits autophagy and promotes heart failure by modulating the p27/CDK2/mTOR axis.

Authors:  M Su; J Wang; C Wang; X Wang; W Dong; W Qiu; Y Wang; X Zhao; Y Zou; L Song; L Zhang; R Hui
Journal:  Cell Death Differ       Date:  2014-11-14       Impact factor: 15.828

2.  Triple twist theory of rho inhibition by the angiotensin II type 2 receptor.

Authors:  Satoru Eguchi
Journal:  Circ Res       Date:  2008-05-23       Impact factor: 17.367

3.  Angiotensin II signalling kicks out p27Kip1 : casein kinase 2 augmentation of Cav 1.2 L-type Ca2+ channel activity in immature ventricular cardiomyocytes.

Authors:  Mary C Horne; Johannes W Hell
Journal:  J Physiol       Date:  2017-05-26       Impact factor: 5.182

Review 4.  Protein kinase CK2 in breast cancer: the CK2β regulatory subunit takes center stage in epithelial plasticity.

Authors:  Odile Filhol; Sofia Giacosa; Yann Wallez; Claude Cochet
Journal:  Cell Mol Life Sci       Date:  2015-05-20       Impact factor: 9.261

5.  HDACs and hypertrophy, kinases and cancer.

Authors:  Berdymammet Hojayev; Joseph A Hill
Journal:  Circulation       Date:  2011-05-16       Impact factor: 29.690

6.  A visionary scientist selects clinicians for clinical research.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2016-04       Impact factor: 4.599

7.  Interaction of ARC and Daxx: A Novel Endogenous Target to Preserve Motor Function and Cell Loss after Focal Brain Ischemia in Mice.

Authors:  Stefan Donath; Junfeng An; Sabrina Lin Lin Lee; Karen Gertz; Anna Lena Datwyler; Ulrike Harms; Susanne Müller; Tracy Deanne Farr; Martina Füchtemeier; Gisela Lättig-Tünnemann; Janet Lips; Marco Foddis; Larissa Mosch; René Bernard; Ulrike Grittner; Mustafa Balkaya; Golo Kronenberg; Ulrich Dirnagl; Matthias Endres; Christoph Harms
Journal:  J Neurosci       Date:  2016-08-03       Impact factor: 6.167

8.  Altered calsequestrin glycan processing is common to diverse models of canine heart failure.

Authors:  Sony Jacob; Naama H Sleiman; Stephanie Kern; Larry R Jones; Javier A Sala-Mercado; Timothy P McFarland; Hani H Sabbah; Steven E Cala
Journal:  Mol Cell Biochem       Date:  2013-03-01       Impact factor: 3.396

9.  Cyclin D2 is a critical mediator of exercise-induced cardiac hypertrophy.

Authors:  Stephen W Luckey; Chris D Haines; John P Konhilas; Elizabeth D Luczak; Antke Messmer-Kratzsch; Leslie A Leinwand
Journal:  Exp Biol Med (Maywood)       Date:  2017-09-13

Review 10.  SUMO--a post-translational modification with therapeutic potential?

Authors:  Chang-Hoon Woo; Jun-Ichi Abe
Journal:  Curr Opin Pharmacol       Date:  2010-01-14       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.